Junshi Biosciences News

Junshi Biosciences Begins Phase 3 Trial of JS203 for Diffuse Large B-Cell Lymphoma

Shanghai Junshi Biosciences announced first patient dosing in its Phase 3 clinical study of JS203 combined with chemotherapy for diffuse large B-cell lymphoma, marking a pivotal clinical milestone for the company's oncology pipeline.

Oct 25, 2026